Reprint of Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2

被引:7
|
作者
Lundstrom, L. [1 ]
Bissantz, C. [2 ]
Beck, J. [1 ]
Dellenbach, M. [1 ]
Woltering, T. J. [2 ]
Wichmann, J. [2 ]
Gatti, S. [1 ,3 ]
机构
[1] NORD Neurosci, F Hoffmann La Roche Ag, pRED, Basel, Switzerland
[2] Roche Innovat Ctr Basel, Discovery Chem, Grenzacherstr 124, CH-4070 Basel, Switzerland
[3] R&D Pierre Fabre Labs, CNS Innovat Unit, Toulouse, France
关键词
Metabotropic glutamate receptor; mGlu(2); mGlu(3); mGluR; Negative allosteric modulators; Positive allosteric modulators; LY354740; LY487379; TRANSMEMBRANE BINDING POCKETS; G-PROTEIN; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DRUG DISCOVERY; MGLU2; RECEPTOR; POTENT; ANTAGONIST; INSIGHTS;
D O I
10.1016/j.neuropharm.2016.08.040
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The metabotropic glutamate receptor 2 (mGlu(2)) plays an important role in the presynaptic control of glutamate release and several mGlu(2) positive allosteric modulators (PAMs) have been under assessment for their potential as antipsychotics. The binding mode of mGlu(2) PAMs is better characterized in functional terms while few data are available on the relationship between allosteric and orthosteric binding sites. Pharmacological studies characterizing binding and effects of two different chemical series of mGlu(2) PAMs are therefore carried out here using the radiolabeled mGlu(2) agonist (3)[H]-LY354740 and mGlu(2) PAM 3[H]-2,2,2-TEMPS. A multidimensional approach to the PAM mechanism of action shows that mGlu(2) PAMs increase the affinity of (3)[H]-LY354740 for the orthosteric site of mGlu(2) as well as the number of (3)[H]-LY354740 binding sites. (3)[H]-2,2,2-TEMPS binding is also enhanced by the presence of LY354740. New residues in the allosteric rat mGlu(2) binding pocket are identified to be crucial for the PAMs ligand binding, among these Tyr(3.40) and Asn(5.46). Also of remark, in the described experimental conditions 5731A (Ser(5.42)) residue is important only for the mGlu(2) PAM LY487379 and not for the compound PAM-1: an example of the structural differences among these mGlu(2) PAMs. This study provides a summary of the information generated in the past decade on mGlu(2) PAMs adding a detailed molecular investigation of PAM binding mode. Differences among mGlu(2) PAM compounds are discussed as well as the mGlu(2) regions interacting with mGlu(2) PAM and NAM agents and residues driving mGlu(2) PAM selectivity. This article is part of the Special Issue entitled 'Metabotropic Glutamate Receptors, 5 years on'. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:115 / 127
页数:13
相关论文
共 50 条
  • [1] Pharmacological and molecular characterization of the positive allosteric modulators of metabotropic glutamate receptor 2
    Lundstrom, L.
    Bissantz, C.
    Beck, J.
    Dellenbach, M.
    Woltering, T. J.
    Wichmann, J.
    Gatti, S.
    NEUROPHARMACOLOGY, 2016, 111 : 253 - 265
  • [2] Positive allosteric modulators of metabotropic glutamate receptor subtype 4: Pharmacological and molecular characterization
    Flor, PJ
    Maj, M
    Dragic, Z
    Bruno, V
    Battaglia, G
    Inderbitzin, W
    von der Putten, H
    Kuhn, R
    Nicoletti, F
    Gasparini, F
    NEUROPHARMACOLOGY, 2002, 43 (02) : 286 - 286
  • [3] Pharmacological and Molecular Characterization of Metabotropic Glutamate Receptor 2/3 Negative Allosteric Modulators
    Lundstroem, L.
    Bissantz, C.
    Beck, J.
    Messer, J.
    Woltering, T. J.
    Wettstein, J. G.
    Goetschi, E.
    Wichmann, J.
    Knoflach, F.
    Gatti, S.
    CURRENT NEUROPHARMACOLOGY, 2011, 9 : 38 - 38
  • [4] Pharmacological characterisation of positive allosteric modulators acting on the metabotropic glutamate receptor 2
    Bennett, K. A.
    Weaver, A.
    Marshall, F.
    Langmead, C. J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S4 - S5
  • [5] Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia
    Fraley, Mark E.
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (09) : 1259 - 1275
  • [6] Progress in the Developement of Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2
    Trabanco, A. A.
    Cid, J. M.
    Lavreysen, H.
    Macdonald, G. J.
    Tresadern, G.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (01) : 47 - 68
  • [7] Chemical Switch of a Metabotropic Glutamate Receptor 2 Silent Allosteric Modulator into Dual Metabotropic Glutamate Receptor 2/3 Negative/Positive Allosteric Modulators
    Schann, Stephan
    Mayer, Stanislas
    Franchet, Christel
    Frauli, Melanie
    Steinberg, Edith
    Thomas, Mireille
    Baron, Luc
    Neuville, Pascal
    JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (24) : 8775 - 8779
  • [8] Positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (mGluR2)
    Rudd, MT
    McCauley, JA
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (09) : 869 - 884
  • [9] Metabotropic Glutamate Receptor 2 Positive Allosteric Modulators: Closing the Gate on Drug Abuse?
    Johnson, Kari A.
    Lovinger, David M.
    BIOLOGICAL PSYCHIATRY, 2015, 78 (07) : 436 - 438
  • [10] Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site
    Knoflach, F
    Mutel, V
    Kew, JNC
    Malherbe, P
    Vieira, E
    Wichmann, J
    Kemp, JA
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (23) : 13402 - 13407